Stock TAKP34 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Takeda Pharmaceutical Company Limited Sao Paulo

Equities

TAKP34

BRTAKPBDR006

Delayed Sao Paulo
Other stock markets
 14:51:04 12/06/2024 BST 		5-day change 1st Jan Change
72.31 BRL +0.88% Intraday chart for Takeda Pharmaceutical Company Limited 0.00% +4.55%
06-18 Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP MT
06-18 Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • The opinion of analysts covering the stock has improved over the past four months.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • With an expected P/E ratio at 45.24 and 69.41 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TAKEDA PHARMACEUTICAL COMPANY LIMITED Stock Takeda Pharmaceutical Company Limited
+4.55% 39.97B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+52.40% 803B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.10% 351B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.48% 324B
B-
ABBVIE INC. Stock AbbVie Inc.
+11.11% 303B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.96% 243B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.25% 228B
A+
NOVARTIS AG Stock Novartis AG
+11.15% 217B
B-
AMGEN INC. Stock Amgen Inc.
+6.83% 164B
C+
PFIZER, INC. Stock Pfizer, Inc.
-3.11% 155B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. TAKP34 Stock
  5. Ratings Takeda Pharmaceutical Company Limited